Strasbourg, France, January 23, 2026, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced ...

Transgene and ProBioGen, a CDMO, inked a license agreement for ProBioGen’s AGE1.CR.pIX ® suspension cell line which will combine ProBioGen’s specific production technology with the manufacturing ...

STRASBOURG, France & TOKYO--(BUSINESS WIRE)--Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and ...

Phase I part showed 100% Disease-Free Survival (DFS) after a minimum of 2-year follow-up – providing clinical proof of principle for TG4050 Randomization of all patients expected to be completed by ...

Strasbourg (France), Tokyo (Japan) and Waltham, Mass (USA), March 5 th, 2024, 7:30 am CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for ...

Clinical proof of principle obtained in Phase I adjuvant head and neck cancer trial with individualized cancer vaccine TG4050 ̶ Further data on 24-month follow-up for all patients of the Phase I part ...

Good morning, and welcome to the Transgene conference call. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Transgene website following ...

*** About Transgene Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene’s programs utilize viral ...

PARIS, March 10 (Reuters) - Novartis has taken an exclusive option to develop Transgene's cancer vaccine TG4010, but the deal fell short of investors' hopes, pulling the shares in the French ...

Anyone trying to buy a souvenir at the official Olympic stores at the Milano Cortina Games will have been exposed to an issue troubling Europe's policymakers: the dominance of foreign payment ...